Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced that it successfully completed an export of PEX010, the Company’s botanical psilocybin drug candidate, to Perth, Western Australia. The shipment is believed to be the first botanical psilocybin to be exported to Australia and was received by Reset Mind Sciences Ltd. (“Reset”), a psychedelic-focused subsidiary of Little Green Pharma, a biotechnology company dedicated to developing natural quality medicines to help those living with chronic conditions. Reset will use Filament’s drug product for research purposes.
“The successful export of PEX010 to Australia is a major achievement for our team and demonstrates our significant regulatory capabilities. To our knowledge, this is the first legal shipment of a botanical psilocybin drug candidate to arrive in Australia, and we are pleased to see a natural option being explored by Australian researchers.”
-Lisa Ranken, Chief Operating Officer at Filament Health
“This shipment of naturally sourced psilocybin, the first of its kind to Australia, is not only a significant milestone for Reset but also for Australia’s burgeoning psilocybin industry,” said Reset’s Chief Operating Officer Dr Leon Warne.
Since July 1, 2023, authorised psychiatrists in Australia have been able to prescribe psilocybin for treatment-resistant depression. Reset is progressing its GMP licence application to manufacture psilocybin products for human consumption from botanically sourced psilocybin while the industry awaits publication of the Australian Therapeutic Goods Administration’s Therapeutic Goods Order governing psilocybin production in Australia.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (Cboe CA:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.